

Name of product	Docetaxel infusion. Aseptically prepared from licensed sterile starting materials.
Concentration	Concentration range 0.3mg/ml to 0.74mg/ml in infusion bags in accordance with national dose banding tables. The Docetaxel concentrate should be added to the bag without withdrawal of equivalence of Sodium Chloride 0.9% w/v Infusion unless withdrawal of some infusion required to accomodate the total dose.
Diluent	Sodium Chloride 0.9% w/v
Volume	80mg to 180mg in 250ml (254ml to 259ml including addition volume) 200mg to 360mg in 500ml (510ml to 518ml including addition volume)
Final container	Non-PVC e.g. polyolefin infusion bag with additive port cover. Ideally infusion bag design will incorporate self sealing giving port to minimise H risks associated with accidental spillage during administration.
Starting materials	Licensed Docetaxel concentrate for solution for Infusion Licensed Sodium Chloride 0.9% w/v Infusion bags
Labelling	Labelling must be compliant with the principles of labelling for safety and the BP General specification on unlicensed medicines. Tall Man lettering must be used drug name.
Label sample	An example label is provided below stating the minimum requirements only (the format is not restrictive and suppliers can use their preferred layout):-   DOCEtaxel xxxmg   in xxxml Sodium Chloride 0.9% w/v   For Intravenous Infusion   Infuse the entire contents of the bag   Check the solution is free from particles before   administering   Store in a Refrigerator at 2-8°C   Protect From Light   Expiry: dd/mm/yyyy   BN: XXXXXXXX   Keep out of the reach and sight of children   Manufacturer's details MS XXXXXX   Caution Cytotoxic: Handle with care
Batch Number	All products will have a unique batch identification number
Latex status of - components - manufacturing process	All materials and manufacturing processes will be latex free or clearly labelled if
Stability	Stability studies should conform to the Standard Protocol for deriving and assess of stability of Aseptic preparations (small molecules) published by the NHS Pharmaceutical QA Committee (4th Edition, April 2017).